Evidence map›Paper›PMID 33865504›Full record

ArticleThe Lancet. Respiratory medicine2021

SARS-CoV-2 seropositivity and subsequent infection risk in healthy young adults: a prospective cohort study.

Andrew G Letizia, Yongchao Ge, Sindhu Vangeti, Carl Goforth, Dawn L Weir, Natalia A Kuzmina, Corey A Balinsky, Hua Wei Chen, Dan Ewing, Alessandra Soares-Schanoski and 25 more

Open access · bronzeAbstract read
In one paragraph

Article in The Lancet. Respiratory medicine, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 107 papers, 3 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
107citing papers in PubMed, 3 pooled it
10.7field-weighted citation impact, top 1% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

107 citing papers in PubMed, 3 syntheses or guidelines pooled it, 170 citations in OpenAlex.

  1. Pooled it
  2. Pooled it
  3. Pooled it
  4. Trial
  5. Trial
  6. Article
  7. Trends in Testing for SARS-CoV-2 Among Healthcare Workers in a Canadian Cohort Study During the COVID-19 Pandemic, June 2020 to November 2023.The Canadian journal of infectious diseases & medical microbiology = Journal canadien des maladies infectieuses et de la microbiologie medicale · 2025
    Article
  8. Article
  9. Article
  10. Article
  11. Article
  12. Article
  13. Article
  14. Article
  15. Article
  16. Article
  17. Article
  18. Article
  19. Article
  20. Article

47 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

35 authors at 6 institutions in 2 countries.

Andrew G LetiziaNaval Medical Research Center, Silver Spring, MD, USA.
Yongchao GeDepartment of Neurology, Icahn School of Medicine at Mount Sinai, New York, NY, USA.
Sindhu VangetiDepartment of Neurology, Icahn School of Medicine at Mount Sinai, New York, NY, USA.
Carl GoforthNaval Medical Research Center, Silver Spring, MD, USA.
Dawn L WeirNaval Medical Research Center, Silver Spring, MD, USA.
Natalia A KuzminaDepartment of Pathology University of Texas Medical Branch and Galveston National Laboratory, Galveston, TX, USA.
Corey A BalinskyNaval Medical Research Center, Silver Spring, MD, USA.
Hua Wei ChenNaval Medical Research Center, Silver Spring, MD, USA.
Dan EwingNaval Medical Research Center, Silver Spring, MD, USA.
Alessandra Soares-SchanoskiDepartment of Neurology, Icahn School of Medicine at Mount Sinai, New York, NY, USA.
Mary-Catherine GeorgeDepartment of Neurology, Icahn School of Medicine at Mount Sinai, New York, NY, USA.
William D GrahamNaval Medical Research Center, Silver Spring, MD, USA.
Franca JonesNaval Medical Research Center, Silver Spring, MD, USA.
Preeti BharajDepartment of Pathology University of Texas Medical Branch and Galveston National Laboratory, Galveston, TX, USA.
Rhonda A LizewskiNaval Medical Research Unit SIX, Lima, Peru.
Stephen E LizewskiNaval Medical Research Unit SIX, Lima, Peru.
Jan MarayagNaval Medical Research Center, Silver Spring, MD, USA.
Nada MarjanovicDepartment of Neurology, Icahn School of Medicine at Mount Sinai, New York, NY, USA.
Clare M MillerDepartment of Neurology, Icahn School of Medicine at Mount Sinai, New York, NY, USA.
Sagie MofsowitzDepartment of Neurology, Icahn School of Medicine at Mount Sinai, New York, NY, USA.
Venugopalan D NairDepartment of Neurology, Icahn School of Medicine at Mount Sinai, New York, NY, USA.
Edgar NunezNaval Medical Research Center, Silver Spring, MD, USA.
Danielle M ParentDepartment of Pathology & Laboratory Medicine, Larner College of Medicine, University of Vermont, Burlington, VT, USA.
Chad K PorterNaval Medical Research Center, Silver Spring, MD, USA.
Ernesto Santa AnaNaval Medical Research Center, Silver Spring, MD, USA.
Megan SchillingNaval Medical Research Center, Silver Spring, MD, USA.
Daniel StadlbauerDepartment of Microbiology, Icahn School of Medicine at Mount Sinai, New York, NY, USA.
Victor A SugihartoNaval Medical Research Center, Silver Spring, MD, USA.
Michael Terminiand Naval Medical Readiness and Training Command Beaufort, Beaufort, SC, USA.
Peifang SunNaval Medical Research Center, Silver Spring, MD, USA.
Russell P TracyDepartment of Pathology & Laboratory Medicine, Larner College of Medicine, University of Vermont, Burlington, VT, USA.
Florian KrammerDepartment of Microbiology, Icahn School of Medicine at Mount Sinai, New York, NY, USA.
Alexander BukreyevDepartment of Pathology University of Texas Medical Branch and Galveston National Laboratory, Galveston, TX, USA.
Irene RamosDepartment of Neurology, Icahn School of Medicine at Mount Sinai, New York, NY, USA.
Stuart C SealfonDepartment of Neurology, Icahn School of Medicine at Mount Sinai, New York, NY, USA.
Naval Medical Research Command · USIcahn School of Medicine at Mount Sinai · USThe University of Texas Medical Branch at Galveston · USNaval Medical Research Unit Six · PEUniversity of Vermont · USTechnical College of the Lowcountry · US

Funding

Defense Advanced Research Projects Agency N6600119C4022Naval Medical Research Center 9700130
6 · The paper itself

Abstract

backgroundWhether young adults who are infected with SARS-CoV-2 are at risk of subsequent infection is uncertain. We investigated the risk of subsequent SARS-CoV-2 infection among young adults seropositive for a previous infection.

methodsThis analysis was performed as part of the prospective COVID-19 Health Action Response for Marines study (CHARM). CHARM included predominantly male US Marine recruits, aged 18-20 years, following a 2-week unsupervised quarantine at home. After the home quarantine period, upon arrival at a Marine-supervised 2-week quarantine facility (college campus or hotel), participants were enrolled and were assessed for baseline SARS-CoV-2 IgG seropositivity, defined as a dilution of 1:150 or more on receptor-binding domain and full-length spike protein ELISA. Participants also completed a questionnaire consisting of demographic information, risk factors, reporting of 14 specific COVID-19-related symptoms or any other unspecified symptom, and brief medical history. SARS-CoV-2 infection was assessed by PCR at weeks 0, 1, and 2 of quarantine and participants completed a follow-up questionnaire, which included questions about the same COVID-19-related symptoms since the last study visit. Participants were excluded at this stage if they had a positive PCR test during quarantine. Participants who had three negative swab PCR results during quarantine and a baseline serum serology test at the beginning of the supervised quarantine that identified them as seronegative or seropositive for SARS-CoV-2 then went on to basic training at Marine Corps Recruit Depot-Parris Island. Three PCR tests were done at weeks 2, 4, and 6 in both seropositive and seronegative groups, along with the follow-up symptom questionnaire and baseline neutralising antibody titres on all subsequently infected seropositive and selected seropositive uninfected participants (prospective study period).

findingsBetween May 11, 2020, and Nov 2, 2020, we enrolled 3249 participants, of whom 3168 (98%) continued into the 2-week quarantine period. 3076 (95%) participants, 2825 (92%) of whom were men, were then followed up during the prospective study period after quarantine for 6 weeks. Among 189 seropositive participants, 19 (10%) had at least one positive PCR test for SARS-CoV-2 during the 6-week follow-up (1·1 cases per person-year). In contrast, 1079 (48%) of 2247 seronegative participants tested positive (6·2 cases per person-year). The incidence rate ratio was 0·18 (95% CI 0·11-0·28; p<0·001). Among seropositive recruits, infection was more likely with lower baseline full-length spike protein IgG titres than in those with higher baseline full-length spike protein IgG titres (hazard ratio 0·45 [95% CI 0·32-0·65]; p<0·001). Infected seropositive participants had viral loads that were about 10-times lower than those of infected seronegative participants (ORF1ab gene cycle threshold difference 3·95 [95% CI 1·23-6·67]; p=0·004). Among seropositive participants, baseline neutralising titres were detected in 45 (83%) of 54 uninfected and in six (32%) of 19 infected participants during the 6 weeks of observation (ID50 difference p<0·0001).

interpretationSeropositive young adults had about one-fifth the risk of subsequent infection compared with seronegative individuals. Although antibodies induced by initial infection are largely protective, they do not guarantee effective SARS-CoV-2 neutralisation activity or immunity against subsequent infection. These findings might be relevant for optimisation of mass vaccination strategies.

fundingDefense Health Agency and Defense Advanced Research Projects Agency.

Indexed as

AdolescentAntibodies, ViralCohort StudiesCOVID-19COVID-19 Serological TestingFemaleHumansMaleProspective StudiesQuarantineRisk AssessmentSARS-CoV-2Young AdultAntibodies, Viral

Identifiers

PMID33865504
PMCPMC8049591
OpenAlexW3152551199

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.